Our Team

Management Team

Chief Executive Officer – Akihiro Ko joined Elixirgen, LLC in 2015 and worked as Chief Operating Officer. Through his management efforts, he optimized the company’s business development and operations. With the establishment of Elixirgen Scientific, LLC, he assumed the position of President in August 2016. He has been responsible for business operations, marketing, and business development at Elixirgen Scientific. In 2017, he joined Elixirgen Therapeutics as Chief Executive Officer. He earned a Bachelor of Science degree from University of Virginia, where he cultivated his interest in stem cell biology and epigenetics through his research involving bivalent domains in cancer stem cells.

Chief Scientific Officer – Minoru S.H. Ko, M.D., Ph.D. is currently Professor and Chair at the Department of Systems Medicine, Keio University School of Medicine. He worked as Assistant Professor and Associate Professor (Tenured) at Wayne State University School of Medicine. He also worked as Senior Investigator (tenured) and Section Chief for nearly 15 years at the National Institute on Aging, a division of the National Institutes of Health. He has published more than 150 peer-reviewed scientific articles and more than 20 other articles and book chapters, including a “Stem Cell Biology” chapter of Harrison’s Principles of Internal Medicine (17th, 18th, 19th editions). He brings more than 30 years of experience in stem cell biology, genetics, molecular and cell biology, and systems biology.

President – Naomi Ko, Ph.D. established Elixirgen Therapeutics with her team at Elixirgen, LLC in January 2017. As the co-founder and Chief Executive Officer of Elixirgen, LLC, she oversaw all operations of the company for five years. Her passion for ZSCAN4 therapy is moving Elixirgen Therapeutics forward towards becoming a clinical phase company. She obtained her Ph.D. in molecular biology from Tokyo University of Science, Japan.

Chief Business Development Officer – Bumpei Noda joined Elixirgen Scientific, LLC as a CEO in 2017. He has been responsible for business development, marketing, sales, and funding for further business growth and acceleration. Bumpei has worked for McKinsey and Company Inc., a global management consulting firm and ngmoco, LLC, a mobile application developer. He led strategy projects for pharmaceutical and chemical industry clients in the consulting firm and utilized such experience with strategic mindset for exponential growth on mobile business by managing global talents. In mid-2017, he joined Elixirgen Therapeutics, LLC as Chief Business Development Officer.


Stephen M. Feinstone, M.D. is currently Adjunct Professor, Department of Biochemistry and Molecular Medicine, George Washington University School of Medicine. He was Senior Investigator, Laboratory of Infectious Diseases,
NIAID, National Institutes of Health (NIH) and also Chief, Laboratory of Hepatitis Viruses, Division of Viral Products, CBER, FDA. He received B.A. from Johns Hopkins University and M.D. from University of Tennessee College of Medicine.

Shigeru B.H. Ko, M.D., Ph.D. got his MD degree at Nagoya University School of Medicine in 1992 and his Ph.D. degree for Internal Medicine at Nagoya University Graduate School of Medicine in 1999. He has been seeing patients as a physician for 25 years (specialist of Pancreatology) at several local clinics to University hospitals including Keio University Hospital. He spent 2.5 years in the department of Physiology, UT Southwestern Medical Center at Dallas, TX as a research fellow from 2000 to 2003. He is currently an Associate Professor at the Department of Systems Medicine, Keio University School of Medicine. His current field of interest in research is Regenerative medicine of the pancreas.

Yoshinari Sato, Ph.D. 

He has worked for Daiichi Pharmaceutical Co., Ltd.(1971 to 2006), and Japan Health Sciences Foundation(2006 to 2012).

Kokichi Nakasuji, Ph.D. is currently Project Professor and IP Advisor at Chiba University. He worked for Daiichi Pharmaceutical Co., Ltd.

Morrison & Foerster, LLP
Corporate and Intellectual Property (IP) Advisors